Cognitive Behavioral Therapy for Irritable Bowel Syndrome
(U54_P3_CBT Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how Cognitive Behavioral Therapy (CBT) can help treat Irritable Bowel Syndrome (IBS) by examining connections between the brain, gut, and gut bacteria. Researchers aim to determine if CBT can alter brain-gut communication and whether these changes vary between men and women. Participants will either receive CBT sessions on their phones or continue with their usual care routine. The trial seeks individuals with IBS symptoms who have no other significant health issues and are not currently using CBT. As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research on IBS treatment.
Will I have to stop taking my current medications?
The trial requires that you stop taking medications that alter GI motility and gastric pH at least 72 hours before any physiologic test visit and during the baseline and treatment intervention. You will need approval from your primary care provider to stop these medications. Rescue medications like bisacodyl and loperamide are allowed during intervention periods but not during baseline or within 3 days of follow-up MRI.
What prior data suggests that Cognitive Behavioral Therapy is safe for IBS patients?
Research has shown that Cognitive Behavioral Therapy (CBT) is generally safe and well-tolerated. CBT, a type of talk therapy, helps people change negative thinking patterns and has been used successfully for various mental health issues, such as depression.
For IBS (Irritable Bowel Syndrome), CBT improves symptoms by addressing the interaction between the brain, gut, and microorganisms in the digestive system. No evidence indicates serious side effects from CBT, and most people tolerate this therapy well.
Since CBT does not involve drugs, it avoids the common side effects associated with medications, making it an attractive option for those concerned about medication side effects. Overall, CBT is considered a safe treatment choice for managing IBS symptoms.12345Why are researchers excited about this trial?
Researchers are excited about using Cognitive Behavioral Therapy (CBT) for irritable bowel syndrome (IBS) because it offers a non-drug approach to managing symptoms. Unlike standard treatments like dietary changes, medications, or probiotics, CBT targets the psychological factors that can influence gut health, helping patients manage stress and anxiety that often exacerbate IBS symptoms. This approach can empower patients with coping strategies and potentially reduce reliance on medication, providing a holistic and sustainable option for managing their condition. Additionally, the treatment is delivered remotely, allowing flexibility and accessibility for patients who might struggle to attend in-person sessions.
What evidence suggests that Cognitive Behavioral Therapy is effective for IBS?
Studies have shown that Cognitive Behavioral Therapy (CBT) effectively treats Irritable Bowel Syndrome (IBS). In this trial, participants in the Cognitive Behavioral Treatment Arm will undergo 8-10 weeks of remote CBT. This therapy reduces IBS symptoms by changing negative thought patterns that can worsen these symptoms. Research indicates that CBT improves the quality of life for IBS patients by decreasing symptoms like stomach pain and discomfort. Notably, CBT focuses on the connection between the brain, digestive system, and gut bacteria. This therapy is particularly helpful as it manages both the emotional and physical symptoms of IBS, leading to a more balanced life.14678
Are You a Good Fit for This Trial?
This trial is for men and women aged 18-55 with IBS, meeting ROME IV criteria. Women must be premenopausal, not pregnant or breastfeeding, and willing to use non-hormonal birth control. Participants should have no major psychiatric diagnoses or significant medical conditions that could interfere with the study.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
MRI and Baseline Assessment
Participants undergo MRI scanning and complete baseline assessments
Treatment
Participants receive 8-10 weeks of remote cognitive behavioral therapy
Post-Treatment MRI
Participants return for a post-CBT MRI visit identical to the baseline assessment
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Cognitive Behavioral Therapy
Cognitive Behavioral Therapy is already approved in European Union, United States, Canada for the following indications:
- Anxiety disorders
- Depressive disorders
- Eating disorders
- Post-traumatic stress disorder (PTSD)
- Obsessive-compulsive disorder (OCD)
- Anxiety disorders
- Depressive disorders
- Eating disorders
- Post-traumatic stress disorder (PTSD)
- Obsessive-compulsive disorder (OCD)
- Substance use disorders
- Anxiety disorders
- Depressive disorders
- Eating disorders
- Post-traumatic stress disorder (PTSD)
- Obsessive-compulsive disorder (OCD)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, Los Angeles
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator